pyridin-4-yl(thiophen-2-yl)methanol | 21314-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: pyridin-4-yl(thiophen-2-yl)methanol
• CAS: 21314-81-8
• 化学式: C₁₀H₉NOS
• 分子量: 191.254
• InChiKey: AFMUZNDJPKEPQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  pyridin-4-yl(thiophen-2-yl)methanol 在 锌 resultant residue 、 水 、 disodium;carbonate 、 乙醚 、 Brine 、 Sodium sulfate-III 作用下， 以 溶剂黄146 为溶剂， 反应 16.0h， 以to get the desired compound as an oily liquid (3.2 g, 87%)的产率得到4-(thiophen-2-ylmethyl)pyridine
  参考文献：
  名称：

  Tetrahydropyridine derivatives as FabI inhibitors

  摘要：

  本发明涉及公式（1）的四氢吡啶衍生物，可作为抗菌剂在治疗和预防疾病或紊乱中具有治疗作用，特别是作为FabI抑制剂。其中X、Y、Z和“n”在规范中给出的含义相同，并且具有在抑制Enoyl-ACP还原酶酶（FabI）活性方面具有优势的疾病或紊乱的治疗用途。本发明还提供了合成和给予FabI抑制剂化合物的方法。本发明还提供了包含至少一种FabI抑制剂化合物和其药学上可接受的载体、稀释剂或辅料的制药配方。

  公开号：

  US09062075B2
• 作为产物：
  描述：

  2-溴噻吩 、 4-吡啶甲醛 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.5h， 以34%的产率得到pyridin-4-yl(thiophen-2-yl)methanol
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS
  [FR] DÉRIVÉS DE PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE FABI

  摘要：

  本发明提供了式(I)的取代吡啶衍生物，其可能作为抗细菌剂，特别是FabI抑制剂，具有治疗用途。式(I)中，R1至R5和L具有说明书中给出的含义，以及用于治疗和预防疾病或失调的药用可接受盐，特别是在有优势使用抗细菌剂，尤其是FabI抑制剂的疾病或失调中的用途。本发明还提供了合成和管理FabI抑制剂化合物的方法。本发明还提供了包含至少一种FabI抑制剂化合物和用于其的药用可接受载体、稀释剂或助剂的药物制剂。

  公开号：

  WO2013080222A1

文献信息

• [EN] TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS<br/>[FR] DÉRIVÉS DE TÉTRAHYDROPYRIDINE SERVANT D'INHIBITEURS DE FABI
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014195844A1

  公开（公告）日：2014-12-11

  The present invention relates to tetrahydropyridine derivatives of formula (1) which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. in which X, Y, Z and "n" have the same meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FabI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明涉及式（1）的四氢吡啶衍生物，可作为抗菌剂，更具体地作为FabI抑制剂的治疗用途。其中X、Y、Z和“n”的含义与说明书中给出的含义相同，并且其药学上可接受的盐和立体异构体在治疗和预防疾病或紊乱方面具有用处，特别是在抑制烯酰-ACP还原酶酶（FabI）活性具有优势的疾病或紊乱的治疗中的应用。本发明还提供了合成和给药FabI抑制化合物的方法。本发明还提供了包含至少一种FabI抑制化合物以及药学上可接受的载体、稀释剂或赋形剂的药物制剂。
• Substituted pyridine derivatives as FabI inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US09062002B2

  公开（公告）日：2015-06-23

  The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. Formula (I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了式（I）的取代吡啶衍生物，其作为抗细菌剂可能具有治疗用途，更具体地作为FabI抑制剂。式（I）中R1至R5和L具有规范中所给出的含义，以及其药学上可接受的盐，在治疗和预防疾病或紊乱方面有用，特别是在存在抗细菌剂优势的疾病或紊乱中使用，更具体地作为FabI抑制剂。本发明还提供了合成和给予FabI抑制剂化合物的方法。本发明还提供了包括至少一种FabI抑制剂化合物和药学上可接受的载体、稀释剂或赋形剂的制药配方。
• SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS
  申请人：Aurigene Discovery Technologies Limited

  公开号：US20140336153A1

  公开（公告）日：2014-11-13

  The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. Formula (I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了式（I）的取代吡啶衍生物，其可作为抗菌剂，更特别地是FabI抑制剂，具有治疗上的用途。式（I）中，R1至R5和L具有规范中所给出的含义，以及其药学上可接受的盐，在特定的疾病或疾病预防治疗中有用，特别是在有优势的抗菌剂，更特别地是FabI抑制剂的疾病或疾病预防治疗中的使用。本发明还提供了合成和给予FabI抑制剂化合物的方法。本发明还提供了包含至少一种FabI抑制剂化合物的药物配方，以及与其药学上可接受的载体、稀释剂或赋形剂一起使用的药物配方。
• Visible-light-induced catalyst-free reductive coupling of aldehydes, ketones and imines with cyanopyridines
  作者：Xiaoting Zou、Yatao Lang、Xinlong Han、Ming-Wei Zheng、Jiayuan Wang、Chao-Jun Li、Huiying Zeng

  DOI：10.1039/d4cc00044g

  日期：——

  and imines with cyanopyridines. Hantzsch esters serve as reductants in this process, eliminating the need for transition-metals or photosensitizers. The method demonstrates extensive compatibility and finds utility in the late-stage functionalization of both natural and pharmaceutical products, offering a sustainable pathway for the diversification of chemical compounds.

  本文介绍了可见光驱动的还原偶联，通过醛、酮和亚胺与氰基吡啶的反应促进吡啶取代的醇和胺的合成。 Hantzsch 酯在此过程中充当还原剂，无需使用过渡金属或光敏剂。该方法表现出广泛的兼容性，并在天然和药物产品的后期功能化中得到应用，为化合物的多样化提供了可持续的途径。
• Flexible N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analog: synthesis and monoamine oxidase catalyzed bioactivation
  作者：S. Mbera Ngale Efange、R. H. Michelson、R. P. Remmel、R. J. Boudreau、A. K. Dutta、A. Freshler

  DOI：10.1021/jm00174a007

  日期：1990.12

  Eighteen analogues of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were synthesized and evaluated as substrates of monoamine oxidase. In general, the flexible analogues, characterized by the presence of a methylene (or ethylene) bridge between the aryl/heteroaryl and tetrahydropyridyl moieties, were better substrates of the enzyme than the conformationally restricted MPTP. It is suggested that the increased oxidative activity of these flexible analogues reflects enhanced binding due to the ability of the C-4-aryl/heteroaryl substituent to gain access to a hydrophobic pocket within the substrate binding site.